Fundraising September 15, 2024 – October 1, 2024 About fundraising

Obinutuzumab pretreatment abrogates tumor lysis risk while...

Blood Advances 2018 / 12 Vol. 2; Iss. 24

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Kater, Arnon P., Kersting, Sabina, van Norden, Yvette, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H., Evers, Ludo M., Croon-de Boer, Fransien, Schreurs, John, van der Spek, Ellen, Visser, Hein,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
2
Journal:
Blood Advances
DOI:
10.1182/bloodadvances.2018019422
Date:
December, 2018
File:
PDF, 829 KB
2018
Conversion to is in progress
Conversion to is failed